Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | Director | June 27, 2018 | June 29, 2018 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | June 12, 2018 | June 14, 2018 |
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Director | October 02, 2026 | October 06, 2026 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director · Chief Executive Officer | February 17, 2026 | February 19, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, COO | June 29, 2018 | July 03, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acorda Therapeutics, Inc.
Report date June 27, 2018 · Filed June 29, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $28.15 · Expires 2028-06-27 | Direct | 15,000 |
Reported balance
After 2018-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-27 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option vest in four equal quarterly installments over 12 months beginning on June 27, 2018, with the first quarterly installment vesting on September 27, 2018.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
INFINITY PHARMACEUTICALS, INC.
Report date June 12, 2018 · Filed June 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,845 |
Reported balance
After 2018-06-12 transaction · row 1
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 22,857 · Balance 45,845 F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-12 | Direct | 4,000 |
Reported balance
After 2018-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-12 · Grant · Acquired 4,000 · Balance 4,000 F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the issuer's non-employee director compensation program, the reporting person has elected to receive this grant of shares in lieu of cash as payment of such person's $40,000 annual retainer for service as a director.
F2: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer.
F3: The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Chair of the Audit Committee of the issuer's Board of Directors.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 27,393 |
Reported balance
After 2026-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-07 · Grant · Acquired 27,393 · Balance 27,393 F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
Solid Biosciences Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 141,585 |
Reported balance
After 2026-10-02 transaction · row 1
1 source rowRow 1 · 2026-10-02 · Exercise / conversion · Acquired 3,440 · Balance 141,585 F1: Restricted stock units convert to common stock on a one-for-one basis. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,440 |
Reported balance
After 2026-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-02 · Exercise / conversion · Disposed 3,440 · Balance 3,440 F1: Restricted stock units convert to common stock on a one-for-one basis. F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert to common stock on a one-for-one basis.
F2: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant.
Stoke Therapeutics, Inc.
Report date February 17, 2026 · Filed February 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.09 · Expires 2036-02-16 | Direct | 193,000 |
Reported balance
After 2026-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-17 · Grant · Acquired 193,000 · Balance 193,000 F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2030-02-15 | Direct | 129,000 |
Reported balance
After 2026-02-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-17 · Grant · Acquired 129,000 · Balance 129,000 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement.
F3: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 29, 2018 · Filed July 03, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,699 |
Ending reported balance
After 2018-06-29 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2018-06-29 · Exercise / conversion · Acquired 23,375 · Balance 70,074 Row 2 · 2018-06-29 · Sale · Disposed 4,741 · Balance 65,333 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89). F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2018-06-29 · Sale · Disposed 18,634 · Balance 46,699 F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1. F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $131.89 · Expires 2025-07-20 | Direct | 10,625 |
Reported balance
After 2018-06-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-29 · Exercise / conversion · Disposed 23,375 · Balance 10,625 F5: The option vests in 16 quarterly installments from 7/21/2015. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 5,306 |
Reported balance
Holding disclosure · report date 2018-06-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,306 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $165.22 (range $165.00 to $165.89).
F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $166.57 (range $166.38 to $166.67).
F5: The option vests in 16 quarterly installments from 7/21/2015.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-415649 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,440 Underlying: Common Stock · 3,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:35 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-415649 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-297456 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 3,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-297456 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:02 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001197032-26-000005 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001193125-26-267503 · ownership.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2026 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| May 07, 2026 Filed May 12, 2026 00:30 UTC | Odyssey Therapeutics, Inc. ODTX · Entity 4850 | GrantStock Option (Right to Buy) · Derivative | 27,393 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001193125-26-217592 · ownership.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,393 Underlying: Common Stock · 27,393 shares Expires 2036-05-06 F1 · derivative.exercise_date: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-140056 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,320 Underlying: Common Stock · 3,441 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. F2 · derivative.expiration_date: The restricted stock units were granted on January 2, 2026 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. Read SEC document |
| April 02, 2026 Filed Apr 2, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,441 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-140056 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 129,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. F4 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-006287 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,264 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 13,761 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,761 Underlying: Common Stock · 13,761 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs"). F2 · derivative.exercise_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. F2 · derivative.expiration_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 18,012 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001193125-26-006287 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,012 Underlying: Common Stock · 18,012 shares Expires 2036-01-02 F2 · derivative.exercise_date: The Smith RSUs (as defined in footnote 3) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 2, 2026 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Fourth Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| October 08, 2025 Filed Oct 14, 2025 20:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 380,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Stock · 380,000 shares Expires 2029-10-06 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award shall vest as to 1/4 of the total award annually on the sixth calendar day of October, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 6, 2026. Read SEC document |
| October 08, 2025 Filed Oct 14, 2025 20:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 570,000 | $0.00 Strike: $30.50 | $0.00 |
DisclosureSEC source: 0001197032-25-000004 · form4-10142025_081006.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 570,000 shares Expires 2035-10-07 F1 · derivative.exercise_date: The option shall vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 of the total award vesting monthly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-233445 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,573 Underlying: Common Stock · 4,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-233445 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| July 06, 2025 Filed Jul 9, 2025 00:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,573 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094690 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,146 Underlying: Common Stock · 4,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| July 06, 2025 Filed Jul 9, 2025 00:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,573 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-094690 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| June 17, 2025 Filed Jun 17, 2025 20:29 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 25,000 | $4.79 Strike: $4.79 | $119,750.00 |
DisclosureSEC source: 0001562180-25-004909 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-16 Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $4.58 | $0.00 |
DisclosureSEC source: 0000950170-25-086248 · ownership.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2035-06-12 F1 · derivative.exercise_date: This option was granted on June 12, 2025 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| April 06, 2025 Filed Apr 8, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 4,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-052050 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,719 Underlying: Common Stock · 4,574 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 6, 2025 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Third Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| April 06, 2025 Filed Apr 8, 2025 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 4,574 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-052050 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| March 20, 2025 Filed Mar 20, 2025 22:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantStock Option (Right to Buy) · Derivative | 238,420 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001415889-25-008715 · form4-03202025_100340.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,420 Underlying: Common Stock · 238,420 shares Expires 2035-03-19 F1 · derivative.exercise_date: The option vests ratably as to 1/12 of the total award on the monthly anniversary of the grant date, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 18,293 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,293 Underlying: Common Stock · 18,293 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs"). F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 22,148 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,148 Underlying: Common Stock · 22,148 shares Expires 2035-01-06 F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on January 6, 2025 ("the Grant Date") and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-003052 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 and vested in equal quarterly installments beginning three months from the date of grant, with the final installment vesting 12 months from the date of grant. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-003052 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-112898 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,255 Underlying: Common Stock · 3,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-112898 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 03, 2024 Filed Jul 5, 2024 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,255 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-081866 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,510 Underlying: Common Stock · 3,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| July 03, 2024 Filed Jul 5, 2024 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-081866 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 16,000 | $5.52 Strike: $5.52 | $88,320.00 |
DisclosureSEC source: 0001562180-24-005361 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-06-25 Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:11 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantDirector Stock Option (Right to Buy) · Derivative | 34,400 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0000950170-24-073006 · ownership.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,400 Underlying: Common Stock · 34,400 shares Expires 2034-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2024 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:23 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,639 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001415889-24-015970 · form4-06072024_080629.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,639 Underlying: Common Stock · 7,639 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:45 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 3,256 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042322 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,765 Underlying: Common Stock · 3,256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 20:45 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 3,256 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-042322 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 13,021 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 4 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,021 Underlying: Common Stock · 13,021 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "Smith RSUs"). F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. F3 · derivative.expiration_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 15,112 | $0.00 Strike: $5.76 | $0.00 |
DisclosureSEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 3 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,112 Underlying: Common Stock · 15,112 shares Expires 2034-01-03 F3 · derivative.exercise_date: The Smith RSUs (as defined in footnote 4) and this option (together with the Smith RSUs, the "Smith Equity Awards") were granted on the Grant Date and vest in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of the early termination of the Second Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the Smith Equity Awards shall accelerate in full. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 15,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-002598 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert to common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2024 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the Second Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| January 03, 2024 Filed Jan 6, 2024 00:02 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 15,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-002598 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert to common stock on a one-for-one basis. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 21:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 26,977 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001562180-23-008311 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,977 Underlying: Common Stock · 26,977 shares Expires 2033-12-07 F1 · derivative.exercise_date: The option was granted pursuant to a consulting agreement effective December 8, 2023 (the "Effective Date"). The option will vest as to 1/12 of the underlying shares of common stock on the first day of each month beginning on January 1, 2024, with the balance of then-unvested shares to vest one year after the Effective Date. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 19:13 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 15,569 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-052171 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,570 Underlying: Common Stock · 15,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted units convert to common on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 19:13 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 15,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-052171 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted units convert to common on a one-for-one basis. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 20:48 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 96,340 | $0.00 Strike: $4.76 | $0.00 |
DisclosureSEC source: 0001209191-23-050170 · doc4.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,340 Underlying: Common Stock · 96,340 shares Expires 2033-09-18 F1 · derivative.exercise_date: The option vests ratably as to 1/12th of the total award on December 19, 2023, with 1/12th of the total award vesting quarterly thereafter, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 17:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 15,570 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-031954 · ownership.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,139 Underlying: Common Stock · 15,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. F2 · derivative.expiration_date: The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 17:40 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 15,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-031954 · ownership.xml · nonDerivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted units convert into common stock on a one-for-one basis. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 00:13 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001562180-23-005478 · primarydocument.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-20 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.